SCHEDULE: Ikarian Capital Boosts Tenax Therapeutics Stake to 15.5%

Ikarian Capital and Neil Shahrestani have reported a 15.5% beneficial ownership stake in Tenax Therapeutics, holding 967,600 shares.

Summary

• Ikarian Capital, LLC and Neil Shahrestani jointly reported beneficial ownership of 967,600 shares of Tenax Therapeutics, Inc. Common Stock.
• This ownership represents 15.5% of the Issuer's outstanding Common Stock.
• The percentage is calculated based on 6,243,575 shares outstanding as of November 11, 2025, as disclosed in Tenax Therapeutics' Form 10-Q.
• Ikarian Capital, an investment adviser, manages these securities through Ikarian Healthcare Master Fund, L.P. and certain separate managed accounts.
• Neil Shahrestani, who indirectly controls Ikarian Capital, is deemed to beneficially own the same securities.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant and sustained institutional investment in Tenax Therapeutics, which can be interpreted positively as a vote of confidence. The statement that shares are held in the ordinary course of business and not for control purposes suggests a long-term, passive investment strategy, which is generally viewed favorably by the market.

Positives

• A significant ownership stake by an institutional investor like Ikarian Capital may signal confidence in Tenax Therapeutics' long-term prospects.
• The filing indicates the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist stance aimed at immediate control changes.

Negatives

• This filing is a disclosure of ownership and does not contain information that would typically be categorized as 'negatives' regarding the issuer's performance or outlook.

Risks

• The concentration of a significant portion of the company's stock (15.5%) in the hands of a single institutional investor and its principal could lead to increased volatility if that investor decides to significantly alter its position.
• While the filing states the shares are not held for control purposes, a large stake always carries the potential for future influence on corporate decisions, which could diverge from other shareholders' interests.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from Tenax Therapeutics or the reporting persons regarding the company's future outlook.

Industry Context

In the biotechnology and pharmaceutical sectors, significant institutional ownership can be a common occurrence, reflecting investor interest in companies with promising pipelines or market positions. A 15.5% stake by an investment adviser like Ikarian Capital suggests a notable conviction in Tenax Therapeutics, potentially due to its drug development programs or strategic direction. Such filings are closely watched by the market as they can indicate institutional sentiment towards a company.

Comparison to Industry Standards

• A 15.5% stake by an institutional investor is a substantial position, often placing the investor among the top shareholders. For a small-cap biotech company like Tenax Therapeutics, this level of institutional backing can be significant, potentially offering a degree of stability or signaling a vote of confidence that might attract other investors.
• Compared to other biotech firms, where institutional ownership can vary widely, a concentrated stake of this size by a single entity is noteworthy. For example, while Vanguard or BlackRock might hold larger aggregate percentages across many funds, a single investment adviser holding 15.5% is a more focused bet.

Stakeholder Impact

• Shareholders: The significant stake by Ikarian Capital could be seen as a positive signal, potentially increasing investor confidence and attracting further investment. However, a large concentrated holding also means that Ikarian Capital's future actions could have a substantial impact on share price and corporate direction.
• Management: While the filing states no intent to influence control, a large shareholder always has the potential to engage with management on strategic matters, which could influence decision-making.
• Employees, Customers, Suppliers, Creditors: This filing is unlikely to have a direct immediate impact on these stakeholders, as it primarily concerns ownership structure rather than operational or financial performance.

Key Dates

Recommendation

The filing indicates a significant institutional stake, which is generally a positive signal of confidence. However, a Schedule 13G is purely an ownership disclosure and does not provide new information on the company's operational performance, financial health, or strategic developments. Without additional context from the company's financial reports or business updates, a 'hold' recommendation is appropriate, acknowledging the institutional backing while awaiting further fundamental data to assess the company's intrinsic value and future prospects.

Keywords

Tenax Therapeutics, Ikarian Capital, Neil Shahrestani, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals